Kellie S. Matthews
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kellie S. Matthews has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
David T. Curiel
The Division of Human Gene Therapy, The University of Alabama at Birmingham, 619 19th Street South, OHB 534, Birmingham, AL 35213, USA
2 shared publicationsRonald D. Alvarez
The Division of Gynecologic Oncology, The University of Alabama at Birmingham, 619 19th Street South, OHB 534, Birmingham, AL 35213, USA
2 shared publicationsAkseli Hemminki
Cancer Gene Therapy Group, Molecular Cancer Biology Program and Transplantation Laboratory and Haartman Institute and Finnish Institute for Molecular Medicine and HUSLAB, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
1 shared publicationBaohong Tian
Southern Research Institute, Birmingham, Alabama
1 shared publicationGene P. Siegal
The Department of Pathology, The University of Alabama at Birmingham
1 shared publicationJ. Michael Straughn
1 shared publication
Latest Publications
- 10 August 2009
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 61 (10) , 836-841
Advancements in adenoviral based virotherapy for ovarian cancer
- 10 August 2009
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 61 (10) , 836-841
Advancements in adenoviral based virotherapy for ovarian cancer
- Open Access
- 15 June 2009
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (12) , 4131-4137
Identifying the Safety Profile of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Anticipation of a Phase I Clinical Trial in Patients with Recurrent Ovarian Cancer
Purpose: The purpose of this study was to evaluate the biodistribution and toxicity of Ad5.SSTR/TK.RGD, an infectivity-enhanced adenovirus expressing a therapeutic suicide gene and somatostatin receptor type 2 (for noninvasive assessment of gene transfer with nuclear imaging) in advance of a planned phase I clinical trial for recurrent ovarian carcinoma. Experimental Design: Cohorts of Syrian hamsters were treated i.p. for 3 consecutive days with Ad5.SSTR/TK.RGD or control buffer with or without the prodrug ganciclovir (GCV) and euthanized on day 4, 19, or 56. Tissue and serum samples were evaluated for the presence of virus using qPCR analysis and were assessed for vector-related tissue or laboratory effects. Results: Levels of Ad5.SSTR/TK.RGD in blood and tissues outside of the abdominal cavity were low, indicating minimal systemic absorption. GCV did not affect Ad5.SSTR/TK.RGD biodistribution. The mean Ad5.SSTR/TK.RGD viral level was 100-fold lower on day 19 than day 4, suggesting vector elimination over time. Animals in the Ad5.SSTR/TK.RGD ± GCV cohort had clinical laboratory parameters and microscopic lesions in the abdominal organs indicative of an inflammatory response. Toxicity in this dose cohort seemed to be reversible over time. Conclusions: These studies provide justification for planned dosing of Ad5.SSTR/TK.RGD for a planned phase I clinical trial and insights regarding anticipated toxicity.
- 15 June 2009
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 15 (12) , 4131-4137
Open AccessIdentifying the Safety Profile of Ad5.SSTR/TK.RGD, a Novel Infectivity-Enhanced Bicistronic Adenovirus, in Anticipation of a Phase I Clinical Trial in Patients with Recurrent Ovarian Cancer
Purpose: The purpose of this study was to evaluate the biodistribution and toxicity of Ad5.SSTR/TK.RGD, an infectivity-enhanced adenovirus expressing a therapeutic suicide gene and somatostatin receptor type 2 (for noninvasive assessment of gene transfer with nuclear imaging) in advance of a planned phase I clinical trial for recurrent ovarian carcinoma. Experimental Design: Cohorts of Syrian hamsters were treated i.p. for 3 consecutive days with Ad5.SSTR/TK.RGD or control buffer with or without the prodrug ganciclovir (GCV) and euthanized on day 4, 19, or 56. Tissue and serum samples were evaluated for the presence of virus using qPCR analysis and were assessed for vector-related tissue or laboratory effects. Results: Levels of Ad5.SSTR/TK.RGD in blood and tissues outside of the abdominal cavity were low, indicating minimal systemic absorption. GCV did not affect Ad5.SSTR/TK.RGD biodistribution. The mean Ad5.SSTR/TK.RGD viral level was 100-fold lower on day 19 than day 4, suggesting vector elimination over time. Animals in the Ad5.SSTR/TK.RGD ± GCV cohort had clinical laboratory parameters and microscopic lesions in the abdominal organs indicative of an inflammatory response. Toxicity in this dose cohort seemed to be reversible over time. Conclusions: These studies provide justification for planned dosing of Ad5.SSTR/TK.RGD for a planned phase I clinical trial and insights regarding anticipated toxicity.
- 1 February 2009
- Published by Elsevier in Gynecologic Oncology
- Vol. 112 (2) , 389-393
The effect of obesity on survival in patients with ovarian cancer
- 1 February 2009
- Published by Elsevier in Gynecologic Oncology
- Vol. 112 (2) , 389-393
The effect of obesity on survival in patients with ovarian cancer